HiberCell, Inc. has recently announced an exciting collaboration with Merck, set to revolutionize the treatment of clear cell renal cell carcinoma (RCC).
This groundbreaking partnership will involve the evaluation of HC-7366, a potent activator of ISR kinase GCN2, in combination with Merck’s renowned oral hypoxia-inducible factor-2α (HIF-2α) inhibitor, WELIREG® (belzutifan). Together, these innovative therapies hold immense potential for patients battling this challenging form of RCC.
The collaboration will commence with a Phase 1b study, which aims to assess the safety, tolerability, and preliminary efficacy of the HC-7366 and WELIREG® combination. The primary objective of this study is to determine the recommended Phase 2 dose (RP2D) for the treatment. With the study slated to open in the first quarter of 2024, clinical sites across the United States will enroll up to 80 participants, offering them the opportunity to access this cutting-edge treatment approach.
Leading the clinical trial will be the esteemed Robert J. Motzer, MD, who will serve as the lead Principal Investigator. Dr. Motzer’s expertise and extensive experience in the field of RCC make him an invaluable asset to this groundbreaking study. His guidance and insights will undoubtedly contribute to the successful outcome of the trial.
With the collaboration between HiberCell, Inc. and Merck, patients with clear cell renal cell carcinoma can look forward to a potential breakthrough in treatment options. The combined power of HC-7366 and WELIREG® offers new hope and the possibility of improved outcomes for individuals battling this challenging disease. The future looks promising as we continue to strive for advancements in medical science and the development of effective therapies for those in need.
